Targeted therapy for CLL: continuous monothera... - CLL Support
Targeted therapy for CLL: continuous monotherapy or fixed duration combination therapy - past, present and future
You need to be a member of this community to see this post.
2 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
From Blood Cancer Journal 29th April 2021
Four strategies have been tested in recent years...
Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
Advances in Targeted Therapy for R/R CLL
(These OncLive presentations are intended for medical...
Determining if you'll never need treatment. It is feasible and safe to stop specialized follow-up of asymptomatic lower risk CLL?
Regular readers will have often heard that around 30% of those diagnosed with CLL never need...
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
Chronic lymphocytic leukemia treatment algorithm 2022
This 29 November 2022 review article published in the Blood Cancer Journal presents an...
Related Posts
B-PLL: Ibrutrinib Monotherapy or Obinutuzumab (aka Gazyva) & Venetoclax Combination as first-line treatment for transformed CLL- Relative risk for secondary bone marrow cancer within 5 years after initial CLL chemoimmunotherapy treatment (typically BR or FCR)
Combination therapy for our CLL- Managing the cardiovascular risk of Bruton's Tyrosine Kinase Inhibitors in chronic lymphocytic leukemia
- Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
